AS1411 aptamer-decorated cisplatin-loaded poly(lactic- co -glycolic acid) Nanoparticles for Targeted Therapy of miR-21-inhibited Ovarian Cancer Cells
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AIM: The overexpression of miRNA-21 correlates with the cisplatin (CIS) resistance in the ovarian cancers. METHODS: AS1411 antinucleolin aptamer-decorated PEGylated poly(lactic-co-glycolic acid) nanoparticles containing CIS (Ap-CIS-NPs) and anti-miR-21 (Ap-anti-miR-21-NPs) were prepared, physicochemically investigated and their cancer-targeting ability was confirmed. CIS-resistant A2780 cells (A2780 R) were infected with anti-miR-21 using Ap-anti-miR-21-NPs to decrease the drug resistance and sensitize the cells to CIS. Afterward, miR-21-inhibited cells were exposed to the Ap-CIS-NPs. RESULTS: Ap-anti-miR-21-NPs could infect the A2780 R cells mainly through nucleolin-mediated endocytosis and inhibit the endogenous miR-21. Targeted delivery of CIS using Ap-CIS-NPs into the miR-21-inhibited cells caused an enhanced mortality. CONCLUSION: The targeted delivery of chemotherapeutics to the oncomiR-inhibited cells may find a robust application in cancer chemo/gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
Devulapally, R., Sekar, N. M., Sekar, T. V., Foygel, K., Massoud, T. F., Willmann, J. K., & Paulmurugan, R. (2015) · ACS Nano · doi:10.1021/nn507465d · Cited by 260
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Lloyd, K. L., Cree, I. A., & Savage, R. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1101-8 · Cited by 87
Cited by
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Non-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Wu, Y., Wan, S., Yang, S., Hu, H., Zhang, C., Lai, J., Zhou, J., Chen, W., Tang, X., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01746-6 · Cited by 301
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
“It was suggested that this combination strategymay be considered as a robust approach for treatment of advanced solid tumors [53].”
BackgroundHashemi, M., Mirdamadi, M. S. A., Talebi, Y., Khaniabad, N., Banaei, G., Daneii, P., Gholami, S., Ghorbani, A., Tavakolpournegari, A., Farsani, Z. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106568 · Cited by 153
Metadata
- Authors
- Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- 13
- Issue
- 21
- Pages
- 2729-2758
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2899684830
- Cited by
- 110
- References
- 8
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AS1411 aptamer-decorated cisplatin-loaded poly(lactic- co -glycolic acid) Nanoparticles for Targeted Therapy of miR-21-inhibited Ovarian Cancer Cells. https://app.cochat.ai/papers/10.2217/nnm-2018-0205
- The paper
- Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2018). AS1411 aptamer-decorated cisplatin-loaded poly(lactic- co -glycolic acid) Nanoparticles for Targeted Therapy of miR-21-inhibited Ovarian Cancer Cells. Nanomedicine. https://doi.org/10.2217/nnm-2018-0205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.